Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti-PD-(L)1 immunotherapy Meeting Abstract
| Authors: | Eskander, R. N.; Lee, J. Y.; Mirza, M.; Lorusso, D.; Mackay, H.; Ray-Coquard, I.; Oaknin, A.; Gonzalez-Martin, A.; Hase-gawa, K.; Corr, B.; Wu, X.; Leary, A.; Hu, T.; Dutta, L.; Okpara, C.; McKenzie, J.; Makker, V. |
| Abstract Title: | Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti-PD-(L)1 immunotherapy |
| Meeting Title: | ESGO 2025 Congress |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 35 |
| Issue: | 2 Suppl. 1 |
| Meeting Dates: | 2025 Feb 20-23 |
| Meeting Location: | Rome, Italy |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2025-02-01 |
| Start Page: | 100432 |
| Language: | English |
| ACCESSION: | WOS:001500615900012 |
| DOI: | 10.1016/j.ijgc.2024.100432 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: #650 -- Source: Wos |
